文献速递脊柱关节炎其他结缔组织病

银屑病关节炎与中轴型脊柱关节炎中肿瘤坏死因子抑制剂达标治疗减量与停药策略:一项随机对照非劣效性试验

Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial.
PubMed 文献 · Ann Rheum Dis · 2022-06-14

该务实开放标签单中心随机对照非劣效性试验纳入122例病情稳定低疾病活动度≥6个月的银屑病关节炎和中轴型脊柱关节炎患者,按2:1随机分为减量达标治疗组(N=81)和不减量达标治疗组(N=41),随访12个月。12个月时低疾病活动度比例减量组69%对比不减量组73%,校正差值5%(贝叶斯95%可信区间-10%至19%),在预设20%非劣效界值下证实非劣效,且减量组日均限定日剂量百分比为53%对比不减量组91%。

要点

  • 12个月低疾病活动度比例减量组69%对比不减量组73%,校正差值5%(贝叶斯95%可信区间-10%至19%),在20%非劣效界值下证实非劣效。
  • 第12个月日均限定日剂量百分比减量组53%对比不减量组91%,减量策略大幅减少肿瘤坏死因子抑制剂用量。
  • 减量方案为疾病活动度引导的达标治疗减量直至停药,与不减量达标治疗策略相比低疾病活动度维持非劣效。

核心结论

  • 带有减量尝试的达标治疗肿瘤坏死因子抑制剂策略在12个月仍维持低疾病活动度患者比例方面非劣效于不减量的达标治疗策略,并大幅减少肿瘤坏死因子抑制剂使用。

研究设计与样本

  • 务实开放标签单中心随机对照非劣效性试验,纳入使用肿瘤坏死因子抑制剂且稳定低疾病活动度≥6个月的银屑病关节炎和中轴型脊柱关节炎患者。
  • 患者按2:1随机分为疾病活动度引导的达标治疗联合减量直至停药组(N=81)和不减量组(N=41),随访至12个月。
  • 主要终点为两组12个月时低疾病活动度患者比例的差值,预设非劣效界值为20%,采用贝叶斯先验估计。

主要发现

  • 共122例患者(银屑病关节炎64例,中轴型脊柱关节炎58例)随机分组。
  • 12个月时低疾病活动度比例减量组69%对比不减量组73%,校正差值5%(贝叶斯95%可信区间-10%至19%),在20%非劣效界值下证实非劣效。
  • 第12个月日均限定日剂量百分比减量组53%对比不减量组91%。

关键数值与推荐

  • 非劣效界值为20%。
  • 12个月低疾病活动度比例减量组69%对比不减量组73%,校正差值5%(贝叶斯95%可信区间-10%至19%)。
  • 第12个月日均限定日剂量百分比减量组53%对比不减量组91%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tumour necrosis factor inhibitors (TNFi) are effective in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), but are associated with a small (0.6%) increase in serious infection risk, patient burden due to need for self-injection and high costs. Treat-to-target (T2T) tapering might ameliorate these drawbacks, but high-quality evidence on T2T tapering strategies is lacking in PsA and axSpA. METHODS: We performed a pragmatic open-label, monocentre, randomised controlled non-inferiority (NI) trial on T2T tapering of TNFi. Patients with PsA and axSpA using a TNFi with ≥6 months stable low disease activity (LDA) were included. Patients were randomised 2:1 to disease activity-guided T2T with or without tapering until withdrawal and followed-up to 12 months. Primary endpoint was the difference in proportion of patients having LDA at 12 months between groups, compared with a prespecified NI margin of 20%, estimated using a Bayesian prior. RESULTS: 122 patients (64 PsA and 58 axSpA) were randomised to a T2T strategy with (N=81) or without tapering (N=41). The proportion of patients in LDA at 12 months was 69% for the tapering and 73% for the no-tapering group: adjusted difference 5% (Bayesian 95% credible interval: -10% to 19%) which confirms NI considering the NI margin of 20%. The mean percentage of daily defined dose was 53% for the tapering and 91% for the no-tapering group at month 12. CONCLUSIONS: A T2T TNFi strategy with tapering attempt is non-inferior to a T2T strategy without tapering with regard to the proportion of patients still in LDA at 12 months, and results in a substantial reduction of TNFi use. TRIAL REGISTRATION NUMBER: NL 6771.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Michielsens CA, den Broeder N, van den Hoogen FH, et al. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. Ann Rheum Dis. 2022. PMID: 35701155. doi:10.1136/annrheumdis-2022-222260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。